Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy

Purpose: To report a case with ischemic macular edema (ME) due to an acute branch retinal vein occlusion (BRVO) which was treated with repeated intravitreal anti-VEGF injections. Methods: Retrospective case presentation. Results: A 66-year-old female patient was treated with repeated intravitreal an...

Full description

Bibliographic Details
Main Authors: Thomas Bertelmann, Hans Ulrich Frank, Hendrik Ansgar Fuchs, Nicolas Feltgen
Format: Article
Language:English
Published: Karger Publishers 2017-04-01
Series:Case Reports in Ophthalmology
Subjects:
Online Access:http://www.karger.com/Article/FullText/475520
id doaj-b24758dbb25d44c986ce05ca8f25e8d0
record_format Article
spelling doaj-b24758dbb25d44c986ce05ca8f25e8d02020-11-24T23:30:58ZengKarger PublishersCase Reports in Ophthalmology1663-26992017-04-018127127810.1159/000475520475520Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF TherapyThomas BertelmannHans Ulrich FrankHendrik Ansgar FuchsNicolas FeltgenPurpose: To report a case with ischemic macular edema (ME) due to an acute branch retinal vein occlusion (BRVO) which was treated with repeated intravitreal anti-VEGF injections. Methods: Retrospective case presentation. Results: A 66-year-old female patient was treated with repeated intravitreal anti-VEGF injections due to ischemic ME following an acute BRVO. Over a period of 2.5 years best corrected visual acuity increased from 0.06 to 0.6 (decimal notation) accompanied by a reduction in central retinal thickness from 546 to 292 µm. Overall 17 anti-VEGF injections were administered to treat repeated recurrence of ME. Macular ischemia did not worsen during this profound intravitreal anti-VEGF therapy. Conclusion: Intravitreal anti-VEGF therapy can be a beneficial treatment strategy even in ischemic ME following an acute BRVO.http://www.karger.com/Article/FullText/475520Branch retinal vein occlusionMacular ischemiaAnti-VEGFCorticosteroidsIntravitreal injectionVisual acuityCentral retinal thicknessCOMRADEMacular thickness
collection DOAJ
language English
format Article
sources DOAJ
author Thomas Bertelmann
Hans Ulrich Frank
Hendrik Ansgar Fuchs
Nicolas Feltgen
spellingShingle Thomas Bertelmann
Hans Ulrich Frank
Hendrik Ansgar Fuchs
Nicolas Feltgen
Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy
Case Reports in Ophthalmology
Branch retinal vein occlusion
Macular ischemia
Anti-VEGF
Corticosteroids
Intravitreal injection
Visual acuity
Central retinal thickness
COMRADE
Macular thickness
author_facet Thomas Bertelmann
Hans Ulrich Frank
Hendrik Ansgar Fuchs
Nicolas Feltgen
author_sort Thomas Bertelmann
title Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy
title_short Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy
title_full Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy
title_fullStr Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy
title_full_unstemmed Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy
title_sort branch retinal vein occlusion, macular ischemia, and intravitreal anti-vegf therapy
publisher Karger Publishers
series Case Reports in Ophthalmology
issn 1663-2699
publishDate 2017-04-01
description Purpose: To report a case with ischemic macular edema (ME) due to an acute branch retinal vein occlusion (BRVO) which was treated with repeated intravitreal anti-VEGF injections. Methods: Retrospective case presentation. Results: A 66-year-old female patient was treated with repeated intravitreal anti-VEGF injections due to ischemic ME following an acute BRVO. Over a period of 2.5 years best corrected visual acuity increased from 0.06 to 0.6 (decimal notation) accompanied by a reduction in central retinal thickness from 546 to 292 µm. Overall 17 anti-VEGF injections were administered to treat repeated recurrence of ME. Macular ischemia did not worsen during this profound intravitreal anti-VEGF therapy. Conclusion: Intravitreal anti-VEGF therapy can be a beneficial treatment strategy even in ischemic ME following an acute BRVO.
topic Branch retinal vein occlusion
Macular ischemia
Anti-VEGF
Corticosteroids
Intravitreal injection
Visual acuity
Central retinal thickness
COMRADE
Macular thickness
url http://www.karger.com/Article/FullText/475520
work_keys_str_mv AT thomasbertelmann branchretinalveinocclusionmacularischemiaandintravitrealantivegftherapy
AT hansulrichfrank branchretinalveinocclusionmacularischemiaandintravitrealantivegftherapy
AT hendrikansgarfuchs branchretinalveinocclusionmacularischemiaandintravitrealantivegftherapy
AT nicolasfeltgen branchretinalveinocclusionmacularischemiaandintravitrealantivegftherapy
_version_ 1725539403815714816